Bristol Myers Squibb (BMY) EPS (Weighted Average and Diluted) (2009 - 2026)
Bristol Myers Squibb (BMY) reported EPS (Weighted Average and Diluted) of $1.31 for Q1 2026, up 9.17% year-over-year from $1.2 in Q1 2025, and up 147.17% on a QoQ basis from $0.53 in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of EPS (Weighted Average and Diluted) data on file, last reported at $1.31 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 9.17% year-over-year to $1.31 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.56 (up 33.33% YoY) and the FY2025 annual result came in at $3.46, up 178.46% from the prior year.
- EPS (Weighted Average and Diluted) improved to $1.31 in Q1 2026 per BMY's latest filing, from $0.53 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.31 in Q1 2026 and bottomed at -$5.89 in Q1 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is $0.83 (2024), against an average of $0.42.
- The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) tumbled 650.47%; it then soared 1225.0% in 2025.
- Tracing BMY's EPS (Weighted Average and Diluted) over 5 years: stood at $0.95 in 2022, then fell by 8.42% to $0.87 in 2023, then sank by 95.4% to $0.04 in 2024, then soared by 1225.0% to $0.53 in 2025, then surged by 147.17% to $1.31 in 2026.
- Per Business Quant, the three latest BMY EPS (Weighted Average and Diluted) figures stand at $1.31 (Q1 2026), $0.53 (Q4 2025), and $1.08 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.31 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.31 |
| Dec 31, 2025 | 0.53 |
| Sep 30, 2025 | 1.08 |
| Jun 30, 2025 | 0.64 |
| Mar 31, 2025 | 1.20 |
| Dec 31, 2024 | 0.04 |
| Sep 30, 2024 | 0.60 |
| Jun 30, 2024 | 0.83 |
| Mar 31, 2024 | -5.89 |
| Dec 31, 2023 | 0.87 |
| Sep 30, 2023 | 0.93 |
| Jun 30, 2023 | 0.99 |
| Mar 31, 2023 | 1.07 |
| Dec 31, 2022 | 0.95 |
| Sep 30, 2022 | 0.75 |
| Jun 30, 2022 | 0.66 |
| Mar 31, 2022 | 0.59 |
| Dec 31, 2021 | 1.07 |
| Sep 30, 2021 | 0.69 |
| Jun 30, 2021 | 0.47 |
| Mar 31, 2021 | 0.89 |
| Dec 31, 2020 | -4.45 |
| Sep 30, 2020 | 0.82 |
| Jun 30, 2020 | -0.04 |
| Mar 31, 2020 | -0.34 |
| Dec 31, 2019 | -0.55 |
| Sep 30, 2019 | 0.83 |
| Jun 30, 2019 | 0.87 |
| Mar 31, 2019 | 1.04 |
| Dec 31, 2018 | 0.71 |
| Sep 30, 2018 | 1.16 |
| Jun 30, 2018 | 0.23 |
| Mar 31, 2018 | 0.91 |
| Dec 31, 2017 | -1.42 |
| Sep 30, 2017 | 0.51 |
| Jun 30, 2017 | 0.56 |
| Mar 31, 2017 | 0.94 |
| Dec 31, 2016 | 0.53 |
| Sep 30, 2016 | 0.72 |
| Jun 30, 2016 | 0.69 |
| Mar 31, 2016 | 0.71 |
| Dec 31, 2015 | -0.12 |
| Sep 30, 2015 | 0.42 |
| Jun 30, 2015 | -0.08 |
| Mar 31, 2015 | 0.71 |
| Dec 31, 2014 | 0.01 |
| Sep 30, 2014 | 0.43 |
| Jun 30, 2014 | 0.20 |
| Mar 31, 2014 | 0.56 |
| Dec 31, 2013 | 0.44 |
| Sep 30, 2013 | 0.42 |
| Jun 30, 2013 | 0.32 |
| Mar 31, 2013 | 0.37 |
| Dec 31, 2012 | 0.56 |
| Sep 30, 2012 | -0.43 |
| Jun 30, 2012 | 0.38 |
| Mar 31, 2012 | 0.64 |
| Dec 31, 2011 | 0.50 |
| Sep 30, 2011 | 0.56 |
| Jun 30, 2011 | 0.52 |
| Mar 31, 2011 | 0.57 |
| Dec 31, 2010 | 0.28 |
| Sep 30, 2010 | 0.55 |
| Jun 30, 2010 | 0.53 |
| Mar 31, 2010 | 0.43 |
| Dec 31, 2009 | 0.33 |
| Sep 30, 2009 | 0.48 |
| Jun 30, 2009 | 0.44 |
| Mar 31, 2009 | 0.32 |